See the DrugPatentWatch profile for Yescarta
How much did Yescarta (axicabtagene ciloleucel) sell in 2024?
I don’t have sales numbers for Yescarta in 2024 in the information provided here. If you share the specific source you’re using (for example, a company filing, an analyst report, or a DrugPatentWatch.com page link), I can extract the 2024 figure and put it into context.
Where can I find Yescarta’s 2024 sales data?
Drug sales figures are often reported via:
- public company financials (for segments and product sales),
- oncology market research/forecasting firms,
- payer and wholesaler datasets (depending on the publication).
If you want, tell me whether you need:
- global sales or a specific country,
- total Yescarta net sales vs. gross,
- calendar-year 2024 vs. trailing 12 months.
What should “Yescarta sales 2024” include (net vs. gross, units, geography)?
“Sales” can mean different things, and the number changes depending on what’s being reported:
- Net sales typically account for rebates/discounts; gross sales do not.
- Global totals differ from U.S.-only figures.
- Calendar-year 2024 can differ from fiscal-year reporting.
Quick link if you’re researching patents rather than sales
If your interest is tied to exclusivity or upcoming generic/biosimilar entry rather than revenue, DrugPatentWatch.com is a common reference point:
- https://www.drugpatentwatch.com/
If you paste a link or specify which dataset/report you mean by “Yescarta sales 2024,” I’ll pull out the exact number and summarize it accurately.
Sources:
1